ReviewOpen biology2025
High-density lipoprotein cholesterol: how studying the 'good cholesterol' could improve cardiovascular health.
Review in Open biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Withaferin A, a candidate drug for lupus nephritis, confers renal protection via Pon1‑mediated attenuation of oxidative stress.International journal of molecular medicine · 2026Article
- Longstanding Transcriptional Activation of APOA1 and PON1 in Human Hepatocytes by CRISPR/dCas9 Technology: Transcriptomic Profile and Crosstalk with Endothelial Cells.International journal of molecular sciences · 2026Article
- The combined discriminative value of LHR, NLR, and platelet count in distinguishing first-episode schizophrenia.Annals of general psychiatry · 2026Article
- Improving Lipid Profiles ThroughFoods (Basel, Switzerland) · 2026Review
- Waist-to-height ratio modifies the association between cardiometabolic indices and incident carotid plaque: evidence from a Chinese cohort.Frontiers in nutrition · 2026Article
- High-density lipoprotein cholesterol levels and prognosis in non-ischemic dilated cardiomyopathy.Frontiers in endocrinology · 2026Article
- Investigating the relationship between blood factors and HDL-C levels in the bloodstream using machine learning methods.Journal of health, population, and nutrition · 2025Article
- Association Between Platelet to High-Density Lipoprotein Cholesterol Ratio and Cardiometabolic Multimorbidity in Middle-Aged and Elderly Chinese Hypertensive Patients.Journal of clinical hypertension (Greenwich, Conn.) · 2025Article
- The prevalence and clinical correlates of severe anxiety symptoms in first-episode drug-naïve schizophrenia: a Chinese population study.BMC psychiatry · 2025Article
- Non-linear correlation between the ratio of high-density lipoprotein cholesterol to C-reactive protein and all-cause mortality in adults: an extensive study based on nationwide data.Population health metrics · 2025Article
- The therapeutic effect of curcumin in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of animal studies.Frontiers in pharmacology · 2025Review
- Effects of compound probiotics on growth performance, immunity, antioxidant capacity and gut microbiota in weaned rabbits.Frontiers in veterinary science · 2025Article
- Independent and joint associations of glucose modified by high-density lipoprotein cholesterol with mortality in heart failure patients: evidence from the Jiangxi, China cohort.Frontiers in endocrinology · 2025Article
- A Cross-Sectional Study of the Association Between Uric Acid-to-High-Density Lipoprotein Cholesterol Ratio and Carotid Atherosclerosis in Patients with Type 2 Diabetes Mellitus.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
High cholesterol levels are associated with an increased risk of cardiovascular disease, specifically atherosclerosis, a leading cause of death worldwide. Atherosclerosis occurs when cholesterol and fat build up in plaques along blood vessel walls, restricting blood flow and preventing nutrients and oxygen from diffusing in and out of the bloodstream. High-density lipoprotein cholesterol (HDL) particles prevent the build-up of such plaques, removing excess cholesterol from the peripheral tissues and delivering it to the liver, where it can be removed from the body. This pathway is known as reverse cholesterol transport (RCT). Because HDL plays a key role in preventing plaque buildup, understanding how this molecule and RCT function in the body could help us develop much-needed new atherosclerosis therapies and prevention strategies. However, HDL metabolism is complex, and research on HDL has been less favoured than research investigating a much better-understood molecule, low-density lipoprotein cholesterol, as a treatment target. More specifically, the receptors involved in the process of taking up HDL within the liver and their relationships to one another, along with the mechanism of whole, or holoparticle uptake of HDL remain to be clarified. In this review, we discuss several outstanding mysteries in HDL metabolism, consider why previous clinical trials to improve cardiovascular health by modulating HDL levels have been unsuccessful and argue that understanding HDL metabolism is essential for crafting interventions to reduce cardiovascular disease risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.